Slashed Activities, Reduced Sales: Commercial Crackdown Dents Drug Makers In China
Plus VBP, unfavorable exchange rates
Executive Summary
Among multinationals, AstraZeneca has reported its commercial activities have been negatively impacted by China's broad anti-corruption campaign, while J&J has seen some affect from the country's volume-based procurement scheme. Roche, Lilly and Novartis have also reported some softness in the last quarter versus the previous three months.
You may also be interested in...
Storm Coming? Commercial Compliance Crackdown Shocks China Pharma Industry
In a new wave of crackdowns on compliance in the pharma sector in China, 10 medical meetings have been cancelled in short order, while sector-wide stock prices have plunged and 100 hospital officials placed under investigation, shocking the industry.
China Seniors' Rising HIV Rates Pose Control Challenges
Although the spread of HIV/AIDS appears to be largely under control in China, increasing infections among the elderly are causing concern due to a range of risk factors, while domestic firms move to expand their drug offerings.
Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.